



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: www.shyuanye.com  
邮箱: shyysw@sina.com

产品名称: MK-5046

产品别名: MK-5046


**生物活性:**

<b>Description</b>	MK-5046 is a novel BRS-3 agonist, binds to BRS-3 with high affinity (mouse Ki = 1.6 nM, human Ki = 25 nM). IC50 value: 1.6 nM (Ki, for mouse), 25 nM (Ki, for human) [1] Target: BRS-3 in vitro: MK-5046 is a novel BRS-3 agonist, with improved BRS-3 potency, specificity, and pharmacokinetic properties that allows in-depth investigation of BRS3 agonism in preclinical species and is also potentially suitable for use in humans. MK-5046 exhibits no appreciable binding activity at the neuromedin B and gastrin-releasing peptide receptors, as well as many other receptors, ion channels, and enzymes. In a cell-based Ca <sup>2+</sup> mobilization functional assay, MK-5046 activates human BRS-3 with similar agonist efficacy as the peptide BRS-3 agonist.[1] MK-5046 is a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity.[2] In vivo: MK-5046 is the first BRS-3 agonist with properties suitable for use in larger mammals. In dogs, MK-5046 treatment produced statistically significant and persistent weight loss, which was initially accompanied by increases in body temperature and heart rate that abated with continued dosing. MK-5046 also effectively reduced body weight in rats and caused modest increases in body temperature, heart rate, and blood pressure. MK-5046 in rodents and dogs and further support BRS-3 agonism as a new approach to the treatment of obesity.[1]																					
<b>In Vitro:</b>  DMSO : 14.29 mg/mL (32.16 mM; Need ultrasonic)	<table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent / Mass</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>Concentration</th><th></th><th></th><th></th></tr></thead><tbody><tr><td>1 mM</td><td>2.2504 mL</td><td>11.2519 mL</td><td>22.5038 mL</td></tr><tr><td>5 mM</td><td>0.4501 mL</td><td>2.2504 mL</td><td>4.5008 mL</td></tr><tr><td>10 mM</td><td>0.2250 mL</td><td>1.1252 mL</td><td>2.2504 mL</td></tr></tbody></table>	Preparing Stock Solutions	Solvent / Mass	1 mg	5 mg	10 mg	Concentration				1 mM	2.2504 mL	11.2519 mL	22.5038 mL	5 mM	0.4501 mL	2.2504 mL	4.5008 mL	10 mM	0.2250 mL	1.1252 mL	2.2504 mL
Preparing Stock Solutions	Solvent / Mass		1 mg	5 mg	10 mg																	
	Concentration																					
1 mM	2.2504 mL	11.2519 mL	22.5038 mL																			
5 mM	0.4501 mL	2.2504 mL	4.5008 mL																			
10 mM	0.2250 mL	1.1252 mL	2.2504 mL																			
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。	储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。																					
<b>In Vivo:</b>  请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂:  ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶  1.请依序添加每种溶剂: 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline  Solubility: ≥ 1.43 mg/mL (3.22 mM); Clear solution  此方案可获得 ≥ 1.43 mg/mL (3.22 mM, 饱和度未知) 的澄清溶液。  以 1 mL 工作液为例, 取 100 μL 14.299999 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀; 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。																						



上海源叶生物科技有限公司  
Shanghai yuanYe Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline)</p> <p>Solubility: ≥ 1.43 mg/mL (3.22 mM); Clear solution</p> <p>此方案可获得 ≥ 1.43 mg/mL (3.22 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 14.299999 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水溶液中, 混合均匀。</p> <p>3.请依序添加每种溶剂: 10% DMSO →90% corn oil</p> <p>Solubility: ≥ 1.43 mg/mL (3.22 mM); Clear solution</p> <p>此方案可获得 ≥ 1.43 mg/mL (3.22 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 μL 14.299999 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。</p>
<b>References</b>	[1]. Guan XM, et al. Antibesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist. <i>J Pharmacol Exp Ther.</i> 2011 Feb;336(2):356-364. [2]. Sebhate IK, et al. Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity. <i>ACS Med Chem Lett.</i> 2010 Oct 18;2(1):43-47.



# 源叶生物